Denosumab and bone loss in uncemented total hip arthroplasty: a secondary 5-year follow-up of a randomized controlled trial

Puntos clave

• To evaluate the effect of denosumab on bone loss after uncemented total hip arthroplasty over five years.
• Secondary analysis of a randomized controlled trial
• Comparison of bone preservation between denosumab and control groups
• Assessment of adjusted between-group differences over a five-year period
• No statistically significant effect of denosumab on periprosthetic bone loss observed
• Confidence interval indicated the lack of clinically relevant differences
• Future effects of extended treatment duration remain uncertain